HM06-19-26 (Helsinn)
Description: Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Patients
with Advanced Solid Tumors with RET gene abnormalities.
Target Patient Population: Any tumor type with RET gene abnormalities
Study Design: Study drug is given orally